Therapeutic biologic for treatment of hepatocellular carcinoma
AssigneeCircular Commitment Company
InventorsKuo-Jang Kao, Yun-Hsin Wang
Life of this patent
Estimating the term…
Abstract
The invention provides conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
Claims15
A method of inducing thrombosis and necrosis of a hepatocellular carcinoma (HCC) tumor with PLVAP-positive vasculature, in a human subject in need thereof, comprising administering an effective amount of a conjugate comprising a coagulating agent conjugated to an antibody that binds an extracellular domain epitope of human PLVAP to the subject, wherein the coagulating agent in the conjugate is a tissue factor (TF) having an amino acid sequence at least 95% identical to SEQ ID NO:
- 1 and the antibody in the conjugate comprises
- CDRs 1-3 of the HCVR comprising the amino acid sequence of SEQ ID NO:
- 5, and CDRs 1-3 of the LCVR comprising the amino acid sequence of SEQ ID NO:
- 6, and wherein the antibody specifically binds to an extracellular domain epitope of a human PLVAP having the sequence set forth in SEQ ID NO:
- 26.
Dependencies are inferred from the claim text.